Search results for "Aspartate Aminotransferases"

showing 10 items of 51 documents

Nephrotoxic and hepatotoxic effects of chromium compounds in rats

1986

The nephrotoxic, hepatotoxic and cardiotoxic actions of hexavalent chromium compounds, as well as their effects on lung, blood and circulation may contribute to the fatal outcome of chromium intoxication. Although trivalent chromium have been regarded as relatively biologically inert, there are a few salts of chromium III that have been found to be carcinogenic when inhaled, ingested or brought in contact with the tissues. Sensitive persons and industry workers have been subjects of dermatitis, respiratory tract injuries and digestive ulcers due to chromium compounds. In this work, the authors have studied the effect of trivalent and hexavalent chromium compounds on rats measuring the trans…

Chromiuminorganic chemicalsTime FactorsChromium CompoundsHealth Toxicology and Mutagenesischemistry.chemical_elementPharmacologyToxicologyNephrotoxicitychemistry.chemical_compoundChromiumotorhinolaryngologic diseasesAnimalsUreaAspartate AminotransferasesHexavalent chromiumCarcinogenCreatininetechnology industry and agricultureAlanine TransaminaseRats Inbred StrainsGeneral MedicinePollutionRatschemistryBiochemistryBlood chemistryCreatinineKidney DiseasesChromium toxicityChemical and Drug Induced Liver InjuryBulletin of Environmental Contamination and Toxicology
researchProduct

Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients

2011

INTRODUCTION: Differentiation between steatosis and non-alcoholic steatohepatitis (NASH) in non-alcoholic fatty liver disease (NAFLD) is important as NASH progress to cirrhosis. No specific laboratory/imaging technique exists either to diagnose NASH or to select patients for liver biopsy. PATIENTS AND METHODS: We evaluated serum ferritin and the features of metabolic syndrome with respect to histological inflammation and/or fibrosis in NAFLD patients. The Kleiner scoring system was used to classify NAFLD in consecutive liver biopsies. One hundred and eleven patients: median age 52.6, 64 males, obesity 62, diabetes mellitus (DM) 58, arterial hypertension 26 and hyperlipidaemia 40%. RESULTS: …

Liver CirrhosisAdultMaleBiopsyHyperlipidemiasFatty Liver/blood/diagnosis/etiology/pathologyRisk AssessmentSeverity of Illness IndexHepatitisBody Mass IndexDiabetes ComplicationsYoung AdultNon-alcoholic Fatty Liver DiseasePredictive Value of TestsRisk FactorsNAFLDLondonMetabolic Syndrome X/blood/*complicationsHumansAspartate AminotransferasesObesityBiological Markers/bloodliver fibrosisAgedMetabolic SyndromeInflammationFerritinChi-Square DistributionPatient SelectionNASHHepatitis/blood/complications/*diagnosisMiddle AgedFibrosisFatty LiverLiver Cirrhosis/blood/*diagnosis/etiologyNomogramsLogistic ModelsHyperlipidemias/blood/complicationsHypertension/blood/complicationsFerritinsHypertensionFerritin; Fibrosis; Inflammation; NAFLD; NASHAspartate Aminotransferases/bloodFemaleDiabetes Complications/blood/diagnosis/etiologyObesity/complicationsBiomarkersFerritins/*blood
researchProduct

Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir

2016

Abstract Background Chronic hepatitis C is a major cause of liver-associated mortality caused by decompensated cirrhosis and hepatocellular carcinoma. With the approval of sofosbuvir, therapeutic efficacy has markedly increased. Early changes in non-invasive biomarkers of liver fibrosis under effective antiviral therapy are widely unknown. Aim To evaluate early changes of fibrosis markers determined by enhanced liver fibrosis (ELF) scores and liver stiffness measurement (FibroScan®) in patients treated with sofosbuvir. Methods A total of 32 hepatitis C patients treated prospectively with sofosbuvir were included. The ELF-panel and FibroScan measurements were performed at baseline, week 4, e…

Liver CirrhosisMaleNon-invasive serum markersmedicine.medical_specialtySofosbuvirLiver fibrosisHepatitis C virusLiver fibrosisHepacivirusmedicine.disease_causeAntiviral AgentsGastroenterology03 medical and health sciences0302 clinical medicineFibrosisInternal medicinemedicineHumansAspartate AminotransferasesProspective StudiesLiver stiffness measurementHepatitisFibroScanHepatologymedicine.diagnostic_testbusiness.industryGastroenterologyHepatitis CHepatitis C ChronicMiddle AgedViral Loadmedicine.diseaseTreatment OutcomeELF030220 oncology & carcinogenesisLiver biopsyHepatocellular carcinomaElasticity Imaging TechniquesRNA ViralFemale030211 gastroenterology & hepatologySofosbuvirbusinessmedicine.drugDigestive and Liver Disease
researchProduct

Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon

2016

BACKGROUND AND AIM: Liver biopsy (LB) has lost popularity to stage liver fibrosis in the era of highly effective anti-hepatitis C virus (HCV) therapy, yet diagnosis of persistent cirrhosis may have important implications following HCV eradication. As performance of serological non-invasive tests (NITs) to predict residual fibrosis in non-viremic HCV patients is unknown, we investigated accuracy of NITs to predict residual fibrosis in cirrhotics after a sustained virological response (SVR) to interferon (IFN). METHODS: Thirty-eight patients with a pre-treatment histological diagnosis of cirrhosis and a 48–104 months post-SVR LB were tested with APRI, CDS, FIB-4, FibroQ, Forns Score, GUCI Ind…

Liver CirrhosisMalePathologyCirrhosisBiopsylcsh:MedicineHepacivirusPathology and Laboratory MedicineGastroenterology0302 clinical medicineEsophageal varicesFibrosisOutcome Assessment Health CareMedicine and Health Scienceslcsh:ScienceSerodiagnosisMultidisciplinarymedicine.diagnostic_testLiver DiseasesHepatitis CMiddle AgedHepatitis C3. Good healthSerologyCirrhosisLiver030220 oncology & carcinogenesisLiver biopsyHepatocellular carcinomaHost-Pathogen InteractionsLiver FibrosisElasticity Imaging Techniques030211 gastroenterology & hepatologyFemaleAnatomyResearch Articlemedicine.medical_specialtyHistologySurgical and Invasive Medical ProceduresGastroenterology and HepatologyAntiviral Agents03 medical and health sciencesDiagnostic MedicineInternal medicineBiopsymedicineHumansSerologic TestsAspartate AminotransferasesAgedbusiness.industryPlatelet Countlcsh:RBiology and Life Sciencesmedicine.diseaseFibrosisROC Curvelcsh:QInterferonsTransient elastographybusinessBiomarkersDevelopmental BiologyPLoS ONE
researchProduct

Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients with No…

2019

Some evidence suggests an interference of obesity and alanine aminotransferase (ALT) levels on the diagnostic accuracy for advanced fibrosis of noninvasive tools such as liver stiffness measurement (LSM) by FibroScan, Fibrosis-4 (FIB-4), and nonalcoholic fatty liver disease fibrosis score (NFS). We assessed whether the diagnostic accuracy of LSM, Fibrosis-4 (FIB-4), and NFS and strategies based on the combination of these tools is affected by obesity and/or ALT levels.METHODS:We analyzed data from 968 patients with a histological diagnosis of nonalcoholic fatty liver disease. FIB-4, NFS, and LSM by FibroScan were measured.RESULTS:LSM was better than both FIB-4 and NFS for staging F3-F4 fibr…

Liver CirrhosisMalemedicine.medical_specialtyBiopsySeverity of Illness IndexGastroenterology03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseasePredictive Value of TestsFibrosisInternal medicineSeverity of illnessBiopsyNonalcoholic fatty liver diseasemedicineHumansAspartate AminotransferasesObesityNASH FIBROSISHepatologymedicine.diagnostic_testbusiness.industryFatty liverGastroenterologyAlanine TransaminaseMiddle Agedmedicine.diseaseLiverROC Curve030220 oncology & carcinogenesisPredictive value of testsElasticity Imaging TechniquesFemale030211 gastroenterology & hepatologySteatosisHepatic fibrosisbusinessBiomarkers
researchProduct

Mesenchymal stem cells display hepato-protective activity in lymphoma bearing xenografts.

2012

A disseminated model of non-Hodgkin's lymphoma with prevalent liver metastasis was generated by intraperitoneal (i.p.) injection of EBV(+) B lymphoblastoid SKW6.4 in nude-SCID mice. The survival of SKW6.4 xenografts (median survival = 27 days) was significantly improved when hyaluronan scaffolds embedded with mesenchimal stem cells (MSC) were implanted in the abdominal area 4 days after SKW6.4 injection (median survival = 39.5 days). Mice implanted with MSC showed a significant improvement of hepatic functionality in lymphoma xenografts, as demonstrated by measurement of serum ALT/AST levels. Co-culture of MSC with lymphoma cells enhanced the release of hepatocyte growth factor (HGF) by MSC…

Liver functionality. Lymphoma-bearing xenograftsPathologymedicine.medical_specialtyTime FactorsCell SurvivalMice NudeCell CommunicationMice SCIDMesenchymal Stem Cell Transplantationlymphoma.Mesenchymal stem cells; hepato-protective; lymphoma.Metastasischemistry.chemical_compoundMicehemic and lymphatic diseasesCell Line Tumorhepato-protectiveHyaluronic acidMedicineAnimalsHumansPharmacology (medical)Aspartate AminotransferasesHyaluronic AcidMesenchymal stem cellPharmacologyMesenchymal stem cells; Liver functionality. Lymphoma-bearing xenograftsTissue Scaffoldsbusiness.industryHepatocyte Growth FactorLymphoblastLymphoma Non-HodgkinMesenchymal stem cellLiver NeoplasmsAlanine TransaminaseMesenchymal Stem Cellsmedicine.diseaseXenograft Model Antitumor AssaysCoculture TechniquesLymphomaOncologychemistryLiverCell cultureHepatocyte growth factorStem cellbusinessBiomarkersmedicine.drugInvestigational new drugs
researchProduct

Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19

2021

Abstract Objective The aim of the study was to assess the role of midregional proadrenomedullin (MR-proADM) in patients with COVID-19. Methods We included 110 patients hospitalized for COVID-19. Biochemical biomarkers, including MR-proADM, were measured at admission. The association of plasma MR-proADM levels with COVID-19 severity, defined as a requirement for mechanical ventilation or in-hospital mortality, was evaluated. Results Patients showed increased levels of MR-proADM. In addition, MR-proADM was higher in patients who died during hospitalization than in patients who survived (median, 2.59 nmol/L; interquartile range, 2.3–2.95 vs median, 0.82 nmol/L; interquartile range, 0.57–1.03; …

Lung DiseasesMalemedicine.medical_specialtySciencemedicine.medical_treatmentMR-proADMClinical BiochemistryComorbidityLabmed/1010Severity of Illness IndexGastroenterologyAdrenomedullinInterquartile rangeInternal medicineSeverity of illnessmedicineHumansAspartate AminotransferasesProtein PrecursorsSurvival analysisAgedRetrospective StudiesMechanical ventilationReceiver operating characteristicbiologyInterleukin-6SARS-CoV-2business.industryPatient SelectionBiochemistry (medical)C-reactive proteinCOVID-19Alanine TransaminaseRetrospective cohort studyMiddle AgedPrognosisSurvival Analysisrespiratory diseaseC-Reactive ProteininflammationHypertensionbiology.proteinbiomarkerBiomarker (medicine)FemaleTriagebusinessBiomarkersAcademicSubjects/MED00690Laboratory Medicine
researchProduct

Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis

2017

OBJECTIVES Non-invasive fibrosis scores are widely used to identify/exclude advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). However, these scores were principally developed and validated in patients aged between 35 and 65 years of age. The objective of this study was to assess the effect of age on the performance of non-invasive fibrosis tests in NAFLD. METHODS Patients were recruited from European specialist hepatology clinics. The cohort was divided into five age-based groups: ≤35 (n=74), 36-45 (n=96), 46-55 (n=197), 56-64 (n=191), and ≥65 years (n=76), and the performance of the aspartate aminotransferase (AST)/alanine transaminase (ALT) ratio, fibrosis 4 (F…

MaleLiver CirrhosisPathologyBiopsyPredictive Value of TestAspartate AminotransferasesGastroenterology0302 clinical medicineFibrosisReference ValuesNon-alcoholic Fatty Liver DiseaseArea under curvePrevalenceMedicineReference ValueAge FactorConfoundingAge FactorsGastroenterologyAlanine TransaminaseFalse Positive ReactionMiddle Aged3. Good healthLiver030220 oncology & carcinogenesisPredictive value of testsArea Under Curve030211 gastroenterology & hepatologyFemaleLiver pathologyHumanAdultmedicine.medical_specialtyLiver Cirrhosi610 Medicine & healthdigestive system03 medical and health sciencesPredictive Value of TestsInternal medicineHumansFalse Positive ReactionsAspartate AminotransferasesAgedHepatologybusiness.industryPlatelet CountNon invasivenutritional and metabolic diseasesAspartate AminotransferaseHepatologymedicine.diseaseFibrosisdigestive system diseasesFatty LiverROC CurveHuman medicinebusinessBiomarkersThe American Journal of Gastroenterology
researchProduct

Validation of clinical scoring systems ART and ABCR after transarterial chemoembolization of hepatocellular carcinoma.

2016

Abstract Purpose To perform an external validation of the Assessment for Retreatment with Transarterial Chemoembolization (ART) and α-fetoprotein (AFP), Barcelona Clinic Liver Cancer (BCLC), Child–Pugh, and response (ABCR) scores and to compare them in terms of prognostic power. Materials and Methods From 2000 to 2015, 871 patients with hepatocellular carcinoma underwent transarterial chemoembolization at a tertiary referral hospital, and 176 met all inclusion and exclusion criteria for both scores and were analyzed. Nineteen percent (n = 34) had BCLC stage A disease and 81% had stage B disease. Thirty-nine patients (22%) presented with elevated AFP levels. Overall survival was calculated. …

MaleOncologyCancer ResearchMultivariate analysisKaplan-Meier EstimateGastroenterologyTertiary Care Centers0302 clinical medicineRisk FactorsMedicineStage (cooking)Aged 80 and overLiver NeoplasmsMiddle AgedTreatment OutcomeOncologyBrier score030220 oncology & carcinogenesisPredictive value of testsHepatocellular carcinomaRetreatmentInclusion and exclusion criteriaFemale030211 gastroenterology & hepatologyalpha-FetoproteinsCardiology and Cardiovascular MedicineAlpha-fetoproteinLiver cancerAdultmedicine.medical_specialtyTreatment responseCarcinoma HepatocellularClinical Decision-MakingTertiary referral hospitalRisk AssessmentDecision Support TechniquesYoung Adult03 medical and health sciencesPredictive Value of TestsInternal medicineHumansRadiology Nuclear Medicine and imagingAspartate AminotransferasesChemoembolization TherapeuticAgedNeoplasm StagingRetrospective StudiesHepatologybusiness.industryPatient SelectionExternal validationReproducibility of ResultsRetrospective cohort studymedicine.diseaseConfidence intervalBCLC Stagedigestive system diseasesSurgerybusinessJournal of Clinical Oncology
researchProduct

Patterns of liver injury in COVID-19 - a German case series.

2020

BACKGROUND: Reports of liver injury in patients with novel coronavirus disease 2019 (COVID-19) are emerging from China and the USA. A wide variety of liver function test abnormalities and few cases of severe liver failure have been reported. No data on the hepatic phenotype from Europe are available at current. METHODS: We report a case series of 44 consecutive patients hospitalized for COVID-19 in Germany. RESULTS: At the time of admission, aspartate aminotransferase greater than the upper limit of normal was present in 70%, while alanine aminotransferase was elevated in 15.8%. Markers of cholestatic liver injury were altered only in a minority of patients. During hospitalization, 31% and …

MalePathologyGerman0302 clinical medicineCOVID-19 TestingLiver Function TestsGermanyMedicineElectronic Health RecordsYoung adultLiver injuryAged 80 and overmedicine.diagnostic_testbiologyGastroenterologyAlanine TransaminaseMiddle AgedOncologyLiver030220 oncology & carcinogenesislanguage030211 gastroenterology & hepatologyFemaleChemical and Drug Induced Liver InjuryCoronavirus InfectionsAdultmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Pneumonia ViralAntiviral Agents03 medical and health sciencesBetacoronavirusYoung AdultInternal medicineHumansAspartate AminotransferasesPandemicsAgedRetrospective Studiesbusiness.industryClinical Laboratory TechniquesSARS-CoV-2COVID-19Retrospective cohort studyOriginal ArticlesHepatologyLiver Failure Acutemedicine.diseaselanguage.human_languageCOVID-19 Drug TreatmentAlanine transaminasebiology.proteinbusinessLiver function testsBiomarkersUnited European gastroenterology journal
researchProduct